For the quarter ending 2025-09-30, PSTV had $11,056K increase in cash & cash equivalents over the period. -$2,575K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,423 | -12,250 |
| Depreciation and amortization | 77 | 223 |
| Stock-based compensation expense | 527 | 300 |
| Noncash financing expenses | 0 | 3,061 |
| Grant receivable | - | 450 |
| Change in fair value of derivative instruments | 0 | 2,631 |
| Accretion of discount on short-term investments | -3 | 22 |
| Reduction in the carrying amount of operating lease right-of-use assets | 9 | 44 |
| Gain on sale of assets | 0 | 16 |
| Other assets | -635 | - |
| Other current assets | - | 265 |
| Accounts payable and accrued expenses | -1,127 | -5,181 |
| Change in operating lease liabilities | -9 | -45 |
| Deferred grant liability | 1,045 | - |
| Net cash used in operating activities | -2,548 | -11,970 |
| Purchases of property and equipment | 27 | 10 |
| Proceeds from sale of property and equipment | 0 | 30 |
| Purchase of short-term investments | 3,312 | 7,756 |
| Redemption of short-term investments | 4,643 | 6,662 |
| Purchase of intangible assets | 7 | - |
| Net cash provided by (used in) investing activities | 1,297 | -1,074 |
| Repayment of credit facility | 0 | 3,292 |
| Payment of financing costs | 2,250 | - |
| Proceeds from issuance of notes payable and warrants | 0 | 3,738 |
| Repayment of notes payable | 0 | 3,703 |
| Proceeds from exercise of series b warrants from may 2024 pipe | - | 882 |
| Proceeds from sale of common stock, pre-funded warrants and warrants | 926 | 15,001 |
| Proceeds from sale of common stock under lincoln park purchase agreement | 16,817 | 2,795 |
| Payment to investors pursuant to letter agreement (note 13) | 2,293 | - |
| Offering costs for sale of common stock | 11 | 220 |
| Net cash provided by financing activities | 12,307 | 15,201 |
| Net increase (decrease) in cash and cash equivalents | 11,056 | 2,157 |
| Cash and cash equivalents at beginning of period | 76 | - |
| Cash and cash equivalents at end of period | 13,289 | - |
PLUS THERAPEUTICS, INC. (PSTV)
PLUS THERAPEUTICS, INC. (PSTV)